Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.
Patrick Neven, MD, PhD
Advertisement
Articles by Patrick Neven, MD, PhD
Advertisement
Latest Updated Articles
Toxicities Associated with Ribociclib From MONALEESA-3 TrialPublished: October 15th 2019 | Updated:
Advertisement
Advertisement
